Asad Niazi, MD, MPH

About Asad

Dr. Asad Niazi is a licensed physician and Master of Public Health practicing through the Beluga Health 50-state telemedicine network. At Trimi Health, Dr. Niazi reviews patient eligibility for compounded GLP-1 weight management therapy, evaluating each new patient's medical history, BMI, and weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease) against FDA labeling thresholds and obesity-medicine clinical guidelines. His clinical focus includes obesity medicine, telemedicine-based chronic care, and metabolic health. He works within Trimi's evidence-based protocols, which align with the Endocrine Society's 2024 Obesity Pharmacotherapy Guideline and the AACE Comprehensive Type 2 Diabetes Algorithm 2024. Dr. Niazi's review covers contraindications such as personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, and severe gastrointestinal disease, and confirms that prescriptions are dispensed only by Trimi's named 503A community sterile compounding pharmacies (VialsRx, Texas State Board pharmacy license #35264, and GreenwichRx). He emphasizes patient education on common GLP-1 adverse effects (nausea, vomiting, gallbladder events, acute kidney injury risk if severe GI side effects cause dehydration) and the importance of dose titration to maximize tolerability. Trimi's compounded medications are prepared per individual prescription and are not FDA-approved as drugs; the active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand formulations (Wegovy/Ozempic and Mounjaro/Zepbound).